Data-Driven Modeling of Amyloid-beta Targeted Antibodies for Alzheimer's Disease
Alzheimer's disease (AD) is driven by the accumulation of amyloid-beta (Abeta) proteins in the brain, leading to memory loss and cognitive decline. While monoclonal antibodies targeting Abetahave been approved, optimizing their use to maximize benefits while minimizing side effects remains a challenge. This study develops a mathematical model to describe Abeta aggregation, capturing its progression from monomers to toxic oligomers, protofibrils, and fibrils using mass-action kinetics and coarse-grained modeling. The model is calibrated with experimental data, incorporating parameter estimation and sensitivity analysis to ensure accuracy. An optimal control framework is introduced to determine the best drug dosing strategy that reduces toxic Abeta aggregates while minimizing adverse effects, such as amyloid-related imaging abnormalities (ARIA). Results indicate that Donanemab achieves the greatest reduction in fibrils. This work provides a quantitative framework for optimizing AD treatment strategies, offering insights into balancing therapeutic efficacy and safety.
Code (0)
등록된 구현이 없습니다.
Tasks
parameter estimationSimilar Papers 제목 키워드 기반
Conditioned Generative Modeling of Molecular Glues: A Realistic AI Approach for Synthesizable Drug-like Molecules
Alzheimer's disease (AD) is marked by the pathological accumulation of amyloid beta-42 (Abeta-42), contributing to synaptic dysfunction and neurodegeneration. While extracellular amyloid plaques are well-studied, increas…
Targeting C99 Mediated Metabolic Disruptions with Ketone Therapy in Alzheimer's Disease
The role of ketone bodies in Alzheimers disease (AD) remains incompletely understood, particularly regarding their influence on amyloid pathology. While beta}hydroxybutyrate (BHB) has been implicated in neuroprotection, …
Three-Dimensional Amyloid-Beta PET Synthesis from Structural MRI with Conditional Generative Adversarial Networks
Motivation: Alzheimer's Disease hallmarks include amyloid-beta deposits and brain atrophy, detectable via PET and MRI scans, respectively. PET is expensive, invasive and exposes patients to ionizing radiation. MRI is che…
SSIMIdentification of Causal Relationship between Amyloid-beta Accumulation and Alzheimer's Disease Progression via Counterfactual Inference
Alzheimer's disease (AD) is a neurodegenerative disorder that is beginning with amyloidosis, followed by neuronal loss and deterioration in structure, function, and cognition. The accumulation of amyloid-beta in the brai…
Causal InferencecounterfactualCounterfactual InferenceOpening Amyloid-Windows to the Secondary Structure of Proteins: The Amyloidogenecity Increases Tenfold Inside Beta-Sheets
Methods from artificial intelligence (AI), in general, and machine learning, in particular, have kept conquering new territories in numerous areas of science. Most of the applications of these techniques are restricted t…